Search Results - "Kieburtz, Karl"

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease by Doody, Rachelle S, Thomas, Ronald G, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Joffe, Steven, Kieburtz, Karl, Raman, Rema, Sun, Xiaoying, Aisen, Paul S, Siemers, Eric, Liu-Seifert, Hong, Mohs, Richard

“…In two phase 3 placebo-controlled, randomized trials in 1012 and 1040 patients with mild-to-moderate Alzheimer's disease, solanezumab, a humanized monoclonal…”
Get full text

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease by Doody, Rachelle S, Raman, Rema, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Joffe, Steven, Kieburtz, Karl, He, Feng, Sun, Xiaoying, Thomas, Ronald G, Aisen, Paul S, Siemers, Eric, Sethuraman, Gopalan, Mohs, Richard

“…In this placebo-controlled trial, the γ-secretase inhibitor semagacestat did not improve cognitive status in patients with Alzheimer's disease and was…”
Get full text

Remote smartphone monitoring of Parkinson’s disease and individual response to therapy by Omberg, Larsson, Chaibub Neto, Elias, Perumal, Thanneer M., Pratap, Abhishek, Tediarjo, Aryton, Adams, Jamie, Bloem, Bastiaan R., Bot, Brian M., Elson, Molly, Goldman, Samuel M., Kellen, Michael R., Kieburtz, Karl, Klein, Arno, Little, Max A., Schneider, Ruth, Suver, Christine, Tarolli, Christopher, Tanner, Caroline M., Trister, Andrew D., Wilbanks, John, Dorsey, E. Ray, Mangravite, Lara M.

“…Remote health assessments that gather real-world data (RWD) outside clinic settings require a clear understanding of appropriate methods for data collection,…”
Get full text

Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss: The Idiopathic Intracranial Hypertension Treatment Trial by Wall, Michael, McDermott, Michael P, Kieburtz, Karl D, Corbett, James J, Feldon, Steven E, Friedman, Deborah I, Katz, David M, Keltner, John L, Schron, Eleanor B, Kupersmith, Mark J

“…IMPORTANCE Acetazolamide is commonly used to treat idiopathic intracranial hypertension (IIH), but there is insufficient information to establish an evidence…”
Get full text

The idiopathic intracranial hypertension treatment trial: clinical profile at baseline by Wall, Michael, Kupersmith, Mark J, Kieburtz, Karl D, Corbett, James J, Feldon, Steven E, Friedman, Deborah I, Katz, David M, Keltner, John L, Schron, Eleanor B, McDermott, Michael P

“…To our knowledge, there are no large prospective cohorts of untreated patients with idiopathic intracranial hypertension (IIH) to characterize the disease. To…”
Get more information

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease by Warren Olanow, C., Kieburtz, Karl, Rascol, Olivier, Poewe, Werner, Schapira, Anthony H., Emre, Murat, Nissinen, Helena, Leinonen, Mika, Stocchi, Fabrizio

“…ABSTRACT The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) study compared the initiation of levodopa (l‐dopa) therapy with…”
Get full text

Huntington's disease: Current and future therapeutic prospects by Kieburtz, Karl, Reilmann, Ralf, Olanow, C. Warren

“…ABSTRACT Huntington's disease is a progressive neurodegenerative disorder for which therapies are woefully inadequate and do not prevent inevitable…”
Get full text

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial by Hauser, Robert A, Dr, Olanow, C Warren, MD, Kieburtz, Karl D, MD, Pourcher, Emmanuelle, MD, Docu-Axelerad, Any, MD, Lew, Mark, MD, Kozyolkin, Olexandr, MD, Neale, Ann, BSN, Resburg, Chris, BS, Meya, Uwe, MD, Kenney, Christopher, MD, Bandak, Stephen, MRCP

“…Summary Background Many patients with Parkinson's disease have motor fluctuations despite treatment with available drugs. Tozadenant (SYN115) is an oral,…”
Get full text

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort by Simuni, Tanya, Caspell-Garcia, Chelsea, Coffey, Christopher S, Weintraub, Daniel, Mollenhauer, Brit, Lasch, Shirley, Tanner, Caroline M, Jennings, Danna, Kieburtz, Karl, Chahine, Lana M, Marek, Kenneth

“…ObjectiveTo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de…”
Get full text

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study by Olanow, C Warren, Prof, Kieburtz, Karl, MD, Odin, Per, MD, Espay, Alberto J, MD, Standaert, David G, MD, Fernandez, Hubert H, MD, Vanagunas, Arvydas, MD, Othman, Ahmed A, PhD, Widnell, Katherine L, MD, Robieson, Weining Z, PhD, Pritchett, Yili, PhD, Chatamra, Krai, PhD, Benesh, Janet, BSMT, Lenz, Robert A, MD, Antonini, Angelo, MD

“…Summary Background Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially…”
Get full text

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease by LeWitt, Peter A., Hauser, Robert A., Grosset, Donald G., Stocchi, Fabrizio, Saint-Hilaire, Marie-Helene, Ellenbogen, Aaron, Leinonen, Mika, Hampson, Neil B., DeFeo-Fraulini, Tia, Freed, Martin I., Kieburtz, Karl D.

“…Background Although levodopa is the most effective oral PD therapy, many patients experience motor fluctuations, including sudden loss of dose effect and…”
Get full text

The triple aim of clinical research by Dorsey, E Ray, Kieburtz, Karl

“…The proposed triple aim of health care—enhanced patient experience, improved population health, and reduced per capita costs—can be applied to clinical…”
Get full text

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD by Schobel, Scott A, Palermo, Giuseppe, Auinger, Peggy, Long, Jeffrey D, Ma, Shiyang, Khwaja, Omar S, Trundell, Dylan, Cudkowicz, Merit, Hersch, Steven, Sampaio, Cristina, Dorsey, E Ray, Leavitt, Blair R, Kieburtz, Karl D, Sevigny, Jeffrey J, Langbehn, Douglas R, Tabrizi, Sarah J

“…OBJECTIVE:To identify an improved measure of clinical progression in early Huntington disease (HD) using data from prospective observational cohort studies and…”
Get full text

New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States by Kieburtz, Karl, Katz, Russell, Olanow, C. Warren

Get full text

Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa by LeWitt, Peter, Liang, Grace S., Olanow, C. Warren, Kieburtz, Karl D., Jimenez, Roland, Olson, Kurt, Klepitskaya, Olga, Loewen, Gordon

“…Levodopa (LD) administered with dopa decarboxylase inhibitor is predominantly metabolized in the periphery by catechol- O -methyltransferase (COMT) to 3- O…”
Get full text

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial by Marks, William J, MD, Bartus, Raymond T, PhD, Siffert, Joao, MD, Davis, Charles S, PhD, Lozano, Andres, MD, Boulis, Nicholas, MD, Vitek, Jerrold, MD, Stacy, Mark, MD, Turner, Dennis, MD, Verhagen, Leonard, MD, Bakay, Roy, MD, Watts, Raymond, MD, Guthrie, Barton, MD, Jankovic, Joseph, MD, Simpson, Richard, MD, Tagliati, Michele, MD, Alterman, Ron, MD, Stern, Matthew, MD, Baltuch, Gordon, MD, Starr, Philip A, MD, Larson, Paul S, MD, Ostrem, Jill L, MD, Nutt, John, MD, Kieburtz, Karl, MD, Kordower, Jeffrey H, PhD, Olanow, C Warren, Dr

“…Summary Background In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via an adeno-associated type-2 vector (AAV2) was well…”
Get full text

Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial by Feigin, Andrew, Evans, Elizabeth E., Fisher, Terrence L., Leonard, John E., Smith, Ernest S., Reader, Alisha, Mishra, Vikas, Manber, Richard, Walters, Kimberly A., Kowarski, Lisa, Oakes, David, Siemers, Eric, Kieburtz, Karl D., Zauderer, Maurice

“…SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase 2 study (no. NCT02481674) established to evaluate pepinemab, a semaphorin 4D…”
Get full text

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study by Poewe, Werner, Stocchi, Fabrizio, Arkadir, David, Ebersbach, Georg, Ellenbogen, Aaron L., Giladi, Nir, Isaacson, Stuart H., Kieburtz, Karl, LeWitt, Peter, Olanow, C. Warren, Simuni, Tanya, Thomas, Astrid, Zlotogorski, Abraham, Adar, Liat, Case, Ryan, Oren, Sheila, Fuchs Orenbach, Shir, Rosenfeld, Olivia, Sasson, Nissim, Yardeni, Tami, Espay, Alberto J.

“…ABSTRACT Background Continuous, subcutaneous (SC) levodopa/carbidopa infusion with ND0612 is under development as a treatment for patients with Parkinson's…”
Get full text

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease by Anon

“…ABSTRACT We examined the effects of 3 dosages of pridopidine, a dopamine‐stabilizing compound, on motor function and other features of Huntington's disease,…”
Get full text

Adverse event reporting in clinical trials in Parkinson's Disease: Time for change by Olanow, C. Warren, Kenney, Christopher, Bandak, Stephen, Kieburtz, Karl D.

Get full text